
Sign up to save your podcasts
Or


Every hospital-based cancer program pays its own institution for space, lab and IT, and almost none can show how the figure was built. Yoel Bakas on why the largest number in a capital file is often the one nobody negotiates. From Medsolve Dynamics. medsolvedynamics.com | [email protected]
Every service agreement has one clause that grows on its own, and it is almost never the clause that gets negotiated. Yoel Bakas on what a five percent annual step actually costs across a five year term, why the arithmetic surprises people who have signed dozens of these, and where the money goes when nobody owns the renewal date. Recorded at the AMAC Summer Seminar 2026. From Medsolve Dynamics. medsolvedynamics.com | [email protected]
The radiopharmaceutical supply chain consolidated on paper on August 3, 2026, when Curium and Lantheus signed a definitive merger agreement. Yoel Bakas on why the period between signing and closing — an outside date of May 2, 2027, with extensions capped at November 30 — is the only window in which a supplier has a structural reason to give you terms, and what to ask for while it is open. From Medsolve Dynamics.
[email protected] | medsolvedynamics.com
A radiation oncology capital price that has not moved in twenty years.
Onboard imaging, arc delivery, the next iteration of arc delivery, a couch upgrade — all half a million dollars. The same couch is $250,000 on the older platform and half a million on the new one. Yoel Bakas spent two decades on the vendor side handing programs that number, and explains what it actually is: an anchor set to shape your budget before you have built the case for the purchase.
Covered: how anchor pricing differs from cost-based pricing, why the number is self-reinforcing, what belongs in a one-page business case for a capital add-on, and how to arrive at a vendor meeting with your own number instead of theirs.
Medsolve Dynamics — capital strategy, financial strategy, revenue and margin growth, and AI reality checks for oncology programs.
[email protected] | medsolvedynamics.com
Yoel Bakas, computer science and an MBA in artificial intelligence, twenty years configuring and pricing this class of technology from the vendor side, on the two questions radiation oncology and theranostics programs should ask before buying AI response-monitoring or workflow software: does it have a billing pathway (or is it an operating expense with no code to bill against), and who owns the output when the software touches a clinical decision. For hospital and freestanding radiation oncology administrators, CFOs, and theranostics program leads evaluating AI, software renewals, and capital vs operating spend. medsolvedynamics.com | [email protected]
The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sticks. Three drug prices to test before the FY28 budget locks, and what a theranostics business plan has to stand on when the drug margin goes to zero. medsolvedynamics.com | [email protected]
Parts lead time and field-engineer coverage, not the uptime percentage in your contract, decide how long a LINAC is actually down. A vendor-side look at how service coverage models are built around the vendor's cost, not your schedule, and what that costs your throughput and margin. LINAC downtime, service coverage, parts logistics, field engineer, uptime SLA, throughput, time toxicity.
medsolvedynamics.com
A radiation oncology service contract that quotes the same rate on a one-year-old LINAC and a twenty-year-old one was never priced on the cost to serve the machine. It was priced to anchor you. How to make a LINAC service price prove it is tied to cost. LINAC service contract, service pricing, capital negotiation, vendor negotiation, AMAC, purchasing framework.
medsolvedynamics.com
Your first capital negotiation is against someone who runs forty a year. This explains where the vendor puts the leverage and how a new administrator levels the field. New administrator, capital negotiation, vendor meeting, supervision coverage, radiation oncology.
A percentage off a list price the vendor set themselves tells you very little. This explains why the value package matters more than the discount in a LINAC capital negotiation, and what a program should structure for instead. Capital strategy, vendor quote, service contract, radiation oncology.
medsolvedynamics.com
[email protected]